CYP2C19 and pancreatic neoplasm: Kattel et al. reported enhanced systemic exposure of nelfinavir due to genetic polymorphism of CYP2C19 in locally advanced pancreatic cancer patients, suggesting that stratification of patients according to the genotype could identify the population likely to be benefitted from nelfinavir treatment [145].